G-CSF Potently Suppresses Osteoblast Activity in the Bone Marrow.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 591-591
Author(s):  
Matthew J. Christopher ◽  
Fulu Liu ◽  
Brenton Short ◽  
Paul J. Simmons ◽  
Ingrid Winkler ◽  
...  

Abstract There is accumulating evidence that interaction of stromal cell derived factor-1 (SDF-1/CXCL12) with its cognate receptor, CXCR4, generates signals that regulate hematopoietic progenitor cell (HPC) trafficking in the bone marrow. During G-CSF induced HPC mobilization, SDF-1 protein expression in the bone marrow decreases, thereby attenuating CXCR4 signaling. We recently reported that G-CSF treatment induced a decrease in bone marrow SDF-1 mRNA that closely mirrored the fall in SDF-1 protein, suggesting that G-CSF targets one or more SDF-1 producing cell population in the bone marrow. However, the identity of cell populations in the bone marrow that express SDF-1 is controversial. In the present study, we address this issue by sorting cells into mature hematopoietic, hematopoietic progenitor, endothelial, and osteoblast cell populations. Real time RT-PCR analyses showed that osteoblasts and to a lesser degree endothelial cells are the major sources of SDF-1 production in the bone marrow. Surprisingly, on a per cell basis, SDF-1 expression per osteoblast was only modestly (less than two-fold) reduced in mice treated with G-CSF. These data raised the possibility that, rather than affecting SDF-1 expression per osteoblast, G-CSF regulated the number of osteoblasts in the bone marrow. To explore this possibility, osteoblast number in the bone marrow was measured by histomorphometry. Indeed, after 5 days of G-CSF treatment, a significant reduction in the number of endosteal osteoblasts was observed [number of osteoblasts per mm bone perimeter ± SEM: 74.8 ± 13.5 (untreated) versus 33.3 ± 3.8 (G-CSF)]. Moreover, expression of osteocalcin (a specific marker of mature osteoblasts) in the bone marrow was sharply reduced during G-CSF treatment: a 47 ± 12 fold reduction in osteocalcin mRNA (relative to b-actin mRNA) was observed in the bone marrow of G-CSF-treated mice compared with untreated mice. Finally, calcein double-labeling experiments showed that the mineral apposition rate was significantly reduced in G-CSF-treated mice. However, RT-PCR analyses showed that the G-CSF receptor is not expressed on osteoblasts. Accordingly, G-CSF had no direct effect on osteoblast activity in vitro. Collectively, these data show that G-CSF potently suppresses osteoblast number/activity in the bone marrow through an indirect mechanism. Since osteoblasts are thought to play a key role in establishing and maintaining the stem cell niche in the bone marrow, these data raise the possibility that G-CSF, by regulating osteoblast function (including SDF-1 expression), may have profound effects on the stem cell niche that ultimately contribute to HPC mobilization.

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4817-4817
Author(s):  
Weiying Zou ◽  
Bei Yang ◽  
Lei Wu ◽  
Ting Chen ◽  
Dalei Zhang ◽  
...  

Abstract Abstract 4817 Introduction: Parathyroid hormone (PTH) is a major regulator of calcium and phosphate metabolism and is secreted by the cells of the parathyroid gland. Recent research showed that PTH treatment may regulate the hematopoietic stem cell niche, leading to beneficial effects on the HSC pool, and increasing stem cell number and the number of stem cells mobilized into the bloodstream. Many studies demonstrated that the serum PTH was decreased but maintained at the lower level suggesting persisting PTH secretion after total parathyroidectomy without autotransplantation. Some research showed that the thymus is another source of PTH. Can the bone marrow cells express PTH mRNA and release PTH and be a third source of PTH production? The aim of this study was to explore whether PTH could be expressed in bone marrow stem cells(BMSCs). Method: BMSCs were separated from adult male SD rat bone marrow and were cultured in DMEM supplemented with 10% fetal bovine serum. The total RNA was extracted using Trizol one-step method. RT-PCR was performed to examine the expression of PTH and GAPDH in BMSCs. The optical densities (ODs) value of RT-PCR product was measured using the Gel Imageware System. The signal intensity of PTH bands was normalized by corresponding GAPDH bands. The ODs in each sample were expressed as a ratio PTH over GAPDH densitometric intensities. The resultant PCR product of PTH was sequenced in both directions. Immunocytochemistry staining was utilized to examine the expression of PTH in the BMSCs from adherent cell fraction of the 2nd passage. Results: The expressions of PTH mRNA in BMSCs were detected in all 11 rats by RT-PCR. The PCR product was 193bp for PTH (Fig 1). The ratio of PTH over GAPDH ODs value ranged from 0.4407 to 3.1506, and the average ODs value (m ± SD) was 1.2617 ± 0.8953. The sequence of the PTH PCR products matched 100% with the PTH sequence in Genebank (Gene ID: 24694 Pth; gb K01268.1 RATPTH3, Rat parathyroid hormone gene, exons II and III). Some of the BMSCs were PTH positive by immunocytochemistry. The PTH positive cells were middle in size and spindle. PTH staining was localized in the cytoplasma and cell membrane of BMSCs cultured (Fig 2). Conclusion: The PTH mRNA and protein were detected in BMSCs. The results suggest that the BMSCs may be a third cell source responsible for the synthesis and secretion of PTH. It would be interesting to know what type of cells in BMSCs is secreating the PTH and to explore the role of PTH in bone marrow stem cell niche. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 665-665 ◽  
Author(s):  
Yoshio Katayama ◽  
Andres Hidalgo ◽  
Paul S. Frenette

Abstract The exact mechanisms mediating G-CSF-induced hematopoietic progenitor cell (HPC) egress from the bone marrow (BM) are incompletely understood. Recent studies have suggested that the degradation of SDF-1 in the BM by G-CSF-induced proteolysis may play an important role. We previously hypothesized that endogenous galactocerebrosides (GCs) might be involved in HPC trafficking since certain sulfogalactolipids share biological properties with fucoidan, a sulfated fucose polymer endowed with mobilization activity, and showed that G-CSF fails to induce HPC mobilization in mice lacking UDP-galactose:ceramide galactosyl transferase (CGT) (Blood 2001 98:811a), the enzyme necessary for GC synthesis. To gain further mechanistic insights, we assessed protease activity and found no difference in elastase release from BM cells and in the degradation of exogenous SDF-1 in BM extracellular fluid (BMEF) between CGT−/− and +/+ littermates. Furthermore, endogenous SDF-1 levels in BMEF of CGT−/− and +/+ mice showed a similar reduction after G-CSF stimulation (>50% in CGT−/− mice, n=7–9, p<0.05) despite a virtual absence of mobilization. These data suggest that the reduction of SDF-1 in bone marrow is not essential for G-CSF-induced mobilization. To evaluate the spacial distribution of SDF-1 expression in mouse BM, we stained SDF-1 using the tyramide amplification system. We found that SDF-1 staining was sparsely distributed in the BM but, surprisingly, strong homogenous staining was observed in the surrounding bone. Staining specificity was confirmed by ELISA (2.6±0.5 vs 5.8±1.0 ng SDF-1 per femur for BMEF and bone protein extracts, respectively, n=8, p<0.05). Following G-CSF stimulation, SDF-1 protein levels were significantly decreased in bone extracts from CGT+/+ littermates (53% reduction, n=4–5, p<0.05), but were virtually unchanged in CGT−/− mice. Quantitative real-time RT-PCR analyses revealed that SDF-1 was transcriptionally downregulated by G-CSF in both BM and bone in CGT+/+ mice but there was no significant reduction in CGT−/− bone. Since osteoblasts may represent a major source of SDF-1, we suspected that osteoblast activity might be altered in CGT−/− mice. We thus measured plasma osteocalcin levels by ELISA and found a significant reduction in CGT−/− mice compared to CGT+/+ littermates (39% reduction, n=6–9, p<0.001). Immunofluorescence experiments revealed that bone lining osteoblasts in CGT−/− mice were flattened and small while in CGT+/+ littermates, these cells displayed a healthy cobblestone-like appearance. Furthermore, there was a trend toward reduction of gene expression in Runx2, a critical transcription factor in osteoblasts, and α1(I) collagen, an osteoblast-specific bone matrix protein, in CGT−/− BM by real-time RT-PCR. These data suggest that dysregulation of bone SDF-1 in CGT−/− mice may be due to constitutive downregulation of osteoblastic activity. Strikingly, Runx2 and α1(I) collagen were dramatically downregulated by G-CSF in CGT+/+ BM (Runx2; 65% reduction, n=4, p<0.001, α1(I) collagen; 92% reduction, n=4, p<0.05 by real-time RT-PCR). G-CSF does not appear to act directly on osteoblasts since G-CSF receptor mRNA was not detectable in primary osteoblast and 4 different osteoblast lineage cell lines. In conclusion, bone SDF-1, rather than that of BM, may regulate HPC mobilization. The abnormal regulation of bone SDF-1 and reduced osteoblastic activity in CGT−/− mice strongly suggest that bone SDF-1 originates from osteoblasts and that a rapid downregulation of osteoblastic activity may play a key role in the egress of stem cells from BM.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3376-3376
Author(s):  
Melania Tesio ◽  
Alexander Kalinkovich ◽  
Amir Schajnovitz ◽  
Ayelet Dar ◽  
Orit Kollet ◽  
...  

Abstract Application of stress signals such as chemotherapy or repetitive cytokine stimulations induces proliferation, differentiation and mobilization of stem cells from their bone marrow (BM) niches to the circulation, as part of host defense and repair. G-CSF is currently the preferred mobilizing agent used in the clinical setting. We report here that the tyrosine kinase c-Met, is functionally involved in hematopoietic progenitor mobilization by G-CSF administration. Interestingly, c-Met expression was restricted to motile murine and human hematopoietic progenitor cells. While on mouse BM leukocytes c-Met expression was barely detectable during homeostasis, very high levels were documented following G-CSF. Similarly, in the BM of chimeric NOD/SCID mice previously engrafted with human cells, c-Met expression was almost absent on immature human CD34+ and maturing human CD45+ cells from control untreated mice but significant levels of the receptor were detected following G-CSF delivery on both cell populations. This selective expression was associated with increased transcriptional levels of the main regulator of c-Met transcription, hypoxia inducible factor-1 alpha, (HIF-1alpha). More importantly, blockage of c-Met signaling in Balb/c or C57/Bl mice reduced G-CSF-induced mobilization: co-injection of neutralizing c-Met antibodies decreased progenitor cell proliferation in the BM and the release to the peripheral circulation of maturing leukocytes, immature progenitors and primitive Sca+/c-kit+/lin− cells. Moreover, c-Met neutralization was also accompanied by reduced secretion of the mobilizing protease MMP-9. Chemotaxis to SDF-1 was also affected by c-Met inhibition. In vivo c-Met blockage decreased migration of murine bone marrow cells to a gradient of SDF-1 in vitro, suggesting a role for c-Met in directional migration. Stem cells anchored to their BM niches are mostly non cycling/non motile, however following G-CSF, the niche undergoes dynamic changes which are essential for stem cell proliferation and egress. Of note, neutralizing c-Met during G-CSF mobilization lead to significant changes of key regulatory components of the stem cell niche. While beta catenin was significantly up-regulated following G-CSF treatment, neutralization of c-Met decreased beta catenin expression on BM hematopoietic cells to levels similar to those observed in control untreated mice. The stem cell anchoring molecule angiopoietin-1 and its receptor Tie-2 were also affected following in vivo c-Met inhibition. BM cells obtain from G-CSF treated mice presented low transcriptional levels of these molecules, whereas c-Met neutralization reduced this inhibitory effect exerted by G-CSF. In conclusion, our data identify c-Met as a new player involved in the regulation of several aspects that characterize G-CSF induced mobilization: proliferation and migration of progenitor cells as well as dynamic changes in the stem cell niche which are required for stress induced proliferation and recruitment of stem cells.


2022 ◽  
pp. 1-10
Author(s):  
Patrick Wuchter ◽  
Anke Diehlmann ◽  
Harald Klüter

<b><i>Background:</i></b> The stem cell niche in human bone marrow provides scaffolds, cellular frameworks and essential soluble cues to support the stemness of hematopoietic stem and progenitor cells (HSPCs). To decipher this complex structure and the corresponding cellular interactions, a number of in vitro model systems have been developed. The cellular microenvironment is of key importance, and mesenchymal stromal cells (MSCs) represent one of the major cellular determinants of the niche. Regulation of the self-renewal and differentiation of HSPCs requires not only direct cellular contact and adhesion molecules, but also various cytokines and chemokines. The C-X-C chemokine receptor type 4/stromal cell-derived factor 1 axis plays a pivotal role in stem cell mobilization and homing. As we have learned in recent years, to realistically simulate the physiological in vivo situation, advanced model systems should be based on niche cells arranged in a three-dimensional (3D) structure. By providing a dynamic rather than static setup, microbioreactor systems offer a number of advantages. In addition, the role of low oxygen tension in the niche microenvironment and its impact on hematopoietic stem cells need to be taken into account and are discussed in this review. <b><i>Summary:</i></b> This review focuses on the role of MSCs as a part of the bone marrow niche, the interplay between MSCs and HSPCs and the most important regulatory factors that need to be considered when engineering artificial hematopoietic stem cell niche systems. <b><i>Conclusion:</i></b> Advanced 3D model systems using MSCs as niche cells and applying microbioreactor-based technology are capable of simulating the natural properties of the bone marrow niche more closely than ever before.


Blood ◽  
2018 ◽  
Vol 131 (19) ◽  
pp. 2111-2119 ◽  
Author(s):  
Rafael Kramann ◽  
Rebekka K. Schneider

Abstract Myofibroblasts are fibrosis-driving cells and are well characterized in solid organ fibrosis, but their role and cellular origin in bone marrow fibrosis remains obscure. Recent work has demonstrated that Gli1+ and LepR+ mesenchymal stromal cells (MSCs) are progenitors of fibrosis-causing myofibroblasts in the bone marrow. Genetic ablation of Gli1+ MSCs or pharmacologic targeting of hedgehog (Hh)-Gli signaling ameliorated fibrosis in mouse models of myelofibrosis (MF). Moreover, pharmacologic or genetic intervention in platelet-derived growth factor receptor α (Pdgfrα) signaling in Lepr+ stromal cells suppressed their expansion and ameliorated MF. Improved understanding of cellular and molecular mechanisms in the hematopoietic stem cell niche that govern the transition of MSCs to myofibroblasts and myofibroblast expansion in MF has led to new paradigms in the pathogenesis and treatment of MF. Here, we highlight the central role of malignant hematopoietic clone-derived megakaryocytes in reprogramming the hematopoietic stem cell niche in MF with potential detrimental consequences for hematopoietic reconstitution after allogenic stem cell transplantation, so far the only therapeutic approach in MF considered to be curative. We and others have reported that targeting Hh-Gli signaling is a therapeutic strategy in solid organ fibrosis. Data indicate that targeting Gli proteins directly inhibits Gli1+ cell proliferation and myofibroblast differentiation, which results in reduced fibrosis severity and improved organ function. Although canonical Hh inhibition (eg, smoothened [Smo] inhibition) failed to improve pulmonary fibrosis, kidney fibrosis, or MF, the direct inhibition of Gli proteins ameliorated fibrosis. Therefore, targeting Gli proteins directly might be an interesting and novel therapeutic approach in MF.


2018 ◽  
Vol 20 (suppl_3) ◽  
pp. iii289-iii289
Author(s):  
V V V Hira ◽  
J R Wormer ◽  
H Kakar ◽  
B Breznik ◽  
B van der Swaan ◽  
...  

2019 ◽  
Vol 25 (4) ◽  
pp. 701-701 ◽  
Author(s):  
Maria Maryanovich ◽  
Ali H. Zahalka ◽  
Halley Pierce ◽  
Sandra Pinho ◽  
Fumio Nakahara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document